Cushing's Syndrome Clinical Trials, Drug development, Latest FDA Approvals and Treatment Options by Delveinsight | Key Companies - Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals

DelveInsight's 'Cushing's Syndrome Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline Cushing's Syndrome therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cushing's Syndrome pipeline domain.

For Cushing's Syndrome emerging drugs, the Cushing's Syndrome pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Cushing's Syndrome Pipeline Report
• Over 6+ Cushing's Syndrome pipeline therapies are in various stages of development, and their anticipated acceptance in the Cushing's Syndrome market would significantly increase market revenue.
• Leading Cushing's Syndrome companies developing novel drug candidates to improve the Cushing's Syndrome treatment landscape include Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, OMass Therapeutics, and others.
• Promising Cushing's Syndrome pipeline therapies in various stages of development include Relacorilant, CRN 04894, Seliciclib, SPI-62, AZD 4017, ST-002, and others.
• In November 2022, Xeris Biopharma Holdings, Inc. announced that the extended evaluation (EE) results of the SONICS study (NCT01838551) evaluating the longer-term effects of levoket#conazole on cortisol levels, biomarkers of Cushing's syndrome
• In September 2022, Sparrow Pharmaceuticals announced that the first patient in the RESCUE trial, a phase 2 clinical trial of SPI-62, a potent and selective HSD-1 inhibitor, for the treatment of ACTH-dependent Cushing's syndrome, has been dosed.
• In August 2022, the long-term outcomes of the open-label extension period of the Phase III LINC 3 study of Isturisa® were published in The European Journal of Endocrinology by Recordati Rare Diseases.

Request a sample and discover the recent breakthroughs happening Cushing's Syndrome pipeline landscape in @ Cushing's Syndrome Pipeline Report - https://www.delveinsight.com/report-store/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Cushing's Syndrome Overview
Cushing syndrome is caused by prolonged exposure to high cortisol levels in the blood. Iatrogenic corticosteroid use is the most common cause of cushingoid features, but some herbal preparations can also raise circulating corticosteroid levels, leading to Cushing syndrome.

Cushing syndrome and hypercortisolism are terms that can be used interchangeably. Cushing disease is caused by an excess of ACTH-dependent cortisol caused by a pituitary adenoma and accounts for 80% of endogenous Cushing syndrome. Cushing syndrome has two main causes: endogenous hypercortisolism and exogenous hypercortisolism.

Endogenous hypercortisolism can be demonstrated with late-night salivary cortisol or a 24-hour urine free cortisol in the evaluation of suspected Cushing's syndrome. Exogenous steroid tapering is the most effective treatment for iatrogenic Cushing syndrome. Chronic steroid use can suppress adrenal function, and it can take several months for normal adrenal function to return.

Cushing's Syndrome Pipeline Analysis: Drug Profile

Relacorilant: Corcept Therapeutics
Relacorilant is a non-steroidal, selective glucocorticoid receptor modulator, which is the cortisol receptor that is activated when cortisol levels are high. Relacorilant does not bind to any other hormone receptors in the body. Corcept is researching relacorilant as a possible treatment for a number of serious conditions, including Cushing's syndrome and advanced adrenal, ovarian, and pancreatic cancer. Corcept owns Relacorilant, which is protected by composition of matter and method of use patents. In the United States, Relacorilant has been designated as an orphan drug for the treatment of Cushing's syndrome and pancreatic cancer. A Phase III study is currently underway to assess the efficacy and safety of Relacorilant in patients with endogenous Cushing syndrome.

SPI-62: Sparrow Pharmaceuticals
SPI-62 is an oral, small molecule, highly potent, and selective HSD-1 inhibitor. It is being developed to treat cortisol excess conditions such as endogenous Cushing's syndrome (Cushing's) and autonomous cortisol secretion (ACS). SPI-62 demonstrated potent targeting of HSD-1 in the brain and liver, as well as significant lowering of cortisol levels in the liver, in five clinical trials. These studies also revealed a favorable safety and tolerability profile and glucose, HbA1c, cholesterol, and triglyceride improvements. It is currently being tested for Cushing syndrome treatment in the Phase II stage of development.

Download Sample Page: https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Cushing's Syndrome Pipeline Therapies and Key Companies
• Datopotamab deruxtecan: Daiichi Sankyo
• JDQ443: Novartis
• MRTX849: Mirati Therapeutics
• INBRX-106: Inhibrx
• GB 1211: Galecto Biotech
• BBP 398: BridgeBio Pharma
• TGRX 326: Shenzhen TargetRx
• SRF388: Surface Oncology
• ABBV 514: AbbVie

Learn more about the Cushing's Syndrome emerging pipeline therapies @Cushing's Syndrome Clinical Trials - https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Cushing's Syndrome Pipeline Therapeutics Assessment
By Product Type
• Monotherapy
• Combination Therapy
By Stage
• Discovery
• Pre-Clinical
• Phase I
• Phase II
• Phase III
• Pre-registration
By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Cushing's Syndrome Pipeline Report
• Coverage: Global
• Key Cushing's Syndrome Companies: Corcept Therapeutics (NASDAQ: CORT), Crinetics Pharmaceuticals (NASDAQ: CRNX), Cyclacel Pharmaceuticals (NASDAQ: CYCC), Sparrow Pharmaceuticals, Stero Therapeutics, OMass Therapeutics, and others.
• Key Cushing's Syndrome Pipeline Therapies: Relacorilant, CRN 04894, Seliciclib, SPI-62, AZD 4017, ST-002, and others.

Dive deep into rich insights for Cushing's Syndrome emerging therapies and assessment, visit @ Cushing's Syndrome Emerging Therapies - https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Introduction
2. Cushing's Syndrome Executive Summary
3. Cushing's Syndrome Overview
4. Cushing's Syndrome Pipeline Therapeutics
5. Cushing's Syndrome Pipeline: Late Stage Products (Phase III)
6. Cushing's Syndrome Pipeline: Mid Stage Products (Phase II)
7. Cushing's Syndrome Pipeline: Early Stage Products (Phase I/II)
8. Cushing's Syndrome Pipeline: Preclinical Stage Products
9. Cushing's Syndrome Pipeline: Discovery Stage Products
10. Cushing's Syndrome Pipeline Therapeutic Assessment
11. Cushing's Syndrome Pipeline: Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight

Trending Reports:
• Cardiac Insufficiency Market: https://www.delveinsight.com/blog/heart-failure-market
• Onycholysis Market: https://www.delveinsight.com/sample-request/onycholysis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Acral Lentiginous Melanoma Market: https://www.delveinsight.com/report-store/acral-lentiginous-melanoma-market
• Central Serous Chorioretinopathy Market: https://www.delveinsight.com/report-store/central-serous-chorioretinopathy-market
• Cervical Cancer Market Size: https://www.delveinsight.com/report-store/cervical-cancer-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Chronic Lymphocytic Leukemia Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Exocrine Pancreatic Insufficiency Market: https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
• Hepatic Encephalopathy Market: https://www.delveinsight.com/report-store/hepatic-encephalopathy-market
• Hyperkalemia Market: https://www.delveinsight.com/blog/hyperkalemia-treatment-market
• Juvenile Rheumatoid Arthritis Market: https://www.delveinsight.com/report-store/juvenile-rheumatoid-arthritis-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Osteosarcoma Market: https://www.delveinsight.com/infographics/osteosarcoma-market
• Treatment Resistant Depression Market: https://www.delveinsight.com/infographics/treatment-resistant-depression-market
• Triple Negative Breast Cancer Market: https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-market
• Acute Lung Injury Market: https://www.delveinsight.com/sample-request/acute-lung-injury-market
• Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.

This release was published on openPR.